Therefore, we armed the oncolytic virus M1 with mGSDME and explored the potential of armed OVs rM1-mGSDME_FL and rM1-mGSDME_NT as promising therapeutic agents for the treatment of breast cancer. This evidence concerns the gene TIPARP and breast carcinoma.